2. Academic Validation
  3. CD70: An emerging target in cancer immunotherapy

CD70: An emerging target in cancer immunotherapy

  • Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007.
J Jacobs 1,  V Deschoolmeester 2,  K Zwaenepoel 3,  C Rolfo 4,  K Silence 5,  S Rottey 6,  F Lardon 7,  E Smits 8,  P Pauwels 2
Affiliations

Affiliations

  • 1 Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Electronic address: julie.jacobs@uantwerpen.be.
  • 2 Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • 3 Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • 4 Department of Oncology, Antwerp University Hospital, Edegem, Belgium; Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
  • 5 arGEN-X BVBA, Ghent, Belgium.
  • 6 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
  • 7 Center for Oncological Research, University of Antwerp, Wilrijk, Belgium.
  • 8 Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium.
PMID: 26213107 DOI: 10.1016/j.pharmthera.2015.07.007
Abstract

Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating Cancer Immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies.

Keywords

CD27; CD70; Cancer immunotherapy; Combination therapy.

Figures
Products